Granules India rose 1.29% to Rs 121.55 at 12:16 IST on BSE after the company's Gagillapur facility, Hyderabad successfully completed USFDA inspection without any observations.
The announcement was made before market hours today, 17 October 2016.Meanwhile, the S&P BSE Sensex was down 124.25 points or 0.45% at 27,549.61
On BSE, so far 3.79 lakh shares were traded in the counter as against average daily volume of 1.36 lakh shares in the past one quarter. The stock hit a high of Rs 125.60 and a low of Rs 121.10 so far during the day. The stock had hit a record high of Rs 164.45 on 1 December 2015. The stock had hit a 52-week low of Rs 101.25 on 12 February 2016. The stock had outperformed the market over the past 30 days till 14 October 2016, rising 2.26% compared with Sensex's 2.6% fall. The scrip, however, underperformed the market in past one quarter, sliding 17.89% as against Sensex's 0.59% decline.
The small-cap company has equity capital of Rs 21.72 crore. Face value per share is Rs 1.
Granules India said that the company's Gagillapur facility, Hyderabad, has successfully completed U S Food and Drug Administration (USFDA) inspection without any observations. This facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates (PFIs).
On a consolidated basis, Granules India's net profit rose 36.51% to Rs 38.96 crore on 6.56% growth in net sales to Rs 343.50 crore in Q1 June 2016 over Q1 June 2015.
Granules India produces finished dosages, pharmaceutical formulation intermediates and active pharmaceutical ingredients for customers in the regulated and semi-regulated markets.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
